PCDHGB6

Across TCGA pan-cancer cohorts, PCDHGB6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PCDHGB6 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PCDHGB6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHGB6 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

ESCA, READ, and COAD are the cancer types where PCDHGB6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.123	0.539	<.001	42	view →
READ	OS	Median	II,III,IV	0.234	0.848	<.001	33	view →
COAD	OS	Median	IV	0.056	0.649	<.001	13	view →
PRAD	DFS	Median	All	0.474	0.888	<.001	6	view →
SKCM	DFS	Median	IV	0.016	0.454	<.001	6	view →
SCLC	DFS	Median	II,III,IV	0.233	0.609	.042	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	DFS	Median	II,III,IV	0.900	0.607	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PCDHGB6–ESCA (DFS)

Open the ESCA breakdown →